The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial
|
|
- Hester Hampton
- 6 years ago
- Views:
Transcription
1 Osteoporos Int () 4: DOI.7/s ORIGINAL ARTICLE The efficacy of calcium supplementation alone in elderly Thai women over a -year period: a randomized controlled trial R. Rajatanavin & L. Chailurkit & S. Saetung & A. Thakkinstian & H. Nimitphong Received: 8 October /Accepted: 8 March /Published online: 7 May # International Osteoporosis Foundation and National Osteoporosis Foundation Abstract Summary Supplementation with elemental calcium 5 mg/ day alone for years is able to decrease bone turnover and is effective in retarding bone loss at lumbar spine and slowing bone loss at femoral neck in elderly Thai women who had low dietary calcium intake. Introduction Most elderly Thais have a total dietary calcium intake of less than the recommended amount. The aim of the study was to investigate the effect of calcium supplementation on bone mineral density and biochemical indices of bone remodeling in Thai postmenopausal women. Methods Four hundred and four healthy postmenopausal women 6 years old or older without osteoporosis were recruited and conducted in a randomized, double-blinded, placebo-controlled trial. They were randomly given elementary calcium 5 mg/day or placebo for years. Dietary calcium intake was calculated from the nutrient compositional analysis of the -day food records. Serum 5 hydroxyvitamin D was measured by radioimmunoassay and bone turnover markers were determined by electrochemiluminescence immunoassay. Results The age of the subjects was 65.8±4.4 years. All baseline characteristics of the subjects in the calciumsupplemented group and the placebo group were not statistically different. At the end of the study, significant decreases in serum C-terminal telopeptide of type I collagen and serum total procollagen type I amino terminal propeptide in the calciumsupplemented group were observed, while there was no change in the placebo group. In addition, plasma parathyroid hormone decreased, although not significantly, only in the calcium-supplemented group. Percent changes from baseline of lumbar spine (L L4) bone mineral density increased.76 % in the calcium-supplemented group and.87 % in the placebo group, whereas the percent changes from baseline of femoral neck decreased. % in the calcium-supplemented group and.9 % in the placebo group. Conclusions supplementation is necessary for the decrease of bone turnover and prevention of bone loss in Thai elderly women. Keywords Bone mineral density. supplementation. Dietary calcium intake. Elderly women R. Rajatanavin : L. Chailurkit () : S. Saetung : H. Nimitphong Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Rama 6 Rd., Rajthevi, Bangkok 4, Thailand laor.cha@mahidol.ac.th R. Rajatanavin rajata.raj@mahidol.ac.th S. Saetung ssaetung@hotmail.com H. Nimitphong hataikarnn@hotmail.com A. Thakkinstian Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Bangkok 4, Thailand ammarin.tha@mahidol.ac.th Introduction is an essential nutrient for bone health throughout life. It is important for attaining peak bone mass and for preventing and treating osteoporosis. Osteoporosis is much more common in elderly postmenopausal women because they experience loss of the beneficial effects of estrogen on the stimulation of intestinal calcium absorption and reduction of renal calcium excretion [] as well as an increase in bone turnover rate []. The dietary calcium requirement increases with aging. Some randomized controlled trials have shown that calcium supplements could prevent bone loss and reduce osteoporosis in subjects with calcium deficiency and in elderly women [ 6]. In addition, a meta-analysis has shown that calcium supplementation
2 87 Osteoporos Int () 4: significantly reduced fracture risk at various skeletal sites by % in postmenopausal women [7]. However, it is still debatable whether or not calcium supplementation can reduce osteoporotic fractures. Previous studies have shown that dietary calcium intake in the elderly Thai population is low (9± 47 mg/day [8]; 6±88 mg/day [9]; 6 49 mg/day []). Although the recommendation of an adequate intake of calcium for Caucasians was approximately,, mg/day for older adults [], it might not be appropriate for older Thais. The effects of calcium supplementation on bone mineral density may vary according to dietary calcium intake []. Increasing calcium beyond a certain point may not provide further benefits to bone []. In addition, the value of supplementation of calcium intake in the prevention of osteoporosis remains uncertain [4, 5]. Therefore, the purpose of the current study was to determine the efficacy of years of 5 mg calcium supplementation in healthy elderly women 6 years old or older by assessing the bone mineral density and the biochemical indexes of calcium homeostasis. Methods Subjects Seven hundred and two physically active healthy postmenopausal women 6 years old or older were recruited by public advertisements. Medical history taking and physical examination were performed in each individual. The exclusion criteria were a history of metastatic or non-osteoporotic metabolic disease; history of kidney stone within the previous 5 years; vertebral fractures (confirmed by radiographs of the thoracolumbar spine at the beginning of the study) ; thyroid or parathyroid disease; the use of calcium or vitamin D supplementation within the previous months; the use of hormone replacement therapy (such as estrogen, SERMs, or testosterone) or any medication influencing bone metabolism (such as bisphosphonate) within the previous 6 months; and the use in the last year of any glucocorticoid, anticonvulsant medication, or fluoride. Women with lumbar spine (L L4) bone mineral density (BMD) less than or equal to.5 SD were also excluded. On the basis of these criteria, 44 women were included in the study. In a double-blind fashion, subjects were randomly divided into two equally sized groups using computer-generated random numbers. Their allocation remained concealed until the final medical examination. Subjects were assigned either to receive 5 mg of elemental calcium in the form of calcium carbonate or similar-looking placebo tablets, taken once daily after the evening meal for years. All the tablets were provided by the British Dispensary (L.P.) Co., Ltd. (Samutprakarn, Thailand). Subjects were told to avoid any other calcium supplementation. Demographic data such as age, sex, reproductive history, and other lifestyle information including alcohol consumption, smoking, and exercise habits were obtained through an interview. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. All subjects were evaluated at baseline and the same measurements were repeated every 6 months over a -year period. Their medical history and clinical side effects which occurred during the study were recorded. Compliance was assessed by tablet counts at each visit. The study was approved by the Ethics Committee of Ramathibodi Hospital, and written informed consent was obtained from each participant before entering the study. Dietary calcium intake A -day food record was obtained on each subject at baseline, and this was repeated at -month intervals throughout the study. All food records were analyzed for nutrient intake using the INMUCAL software, which was developed by the Institute of Nutrition, Mahidol University, Bangkok, Thailand [6]. Biochemical measurement Blood and 4-h urine samples were collected at baseline and at and years of the study. Blood samples were taken between 8 and AM after overnight fasting. Serum calcium, creatinine, inorganic phosphorus, alkaline phosphatase, and urinary calcium and creatinine were analyzed on an automated biochemical analyzer (Dimension RxL, Dadebehring Co. Ltd., USA). Urinary calcium was expressed as a ratio with urinary creatinine. Serum 5-hydroxyvitamin D [5(OH)D] was measured by radioimmunoassay (DiaSorin Inc., Stillwater, MN) with an intra-assay precision of 8.9 %. Plasma intact parathyroid hormone (PTH), serum C- terminal telopeptide of type I collagen (CTx) and serum total procollagen type I amino terminal propeptide (PINP) levels were determined by electrochemiluminescence immunoassay on an Elecsys analzer (Roche Diagnostic GmbH, Mannheim, Germany). The assays have intra-assay precisions of.6, 5.4, and.8 %, respectively. Bone mineral density BMD at the lumbar spine (L L4) and femoral neck was measured using dual-energy X-ray absorptiometry (Lunar Corp., Madison, WI) at baseline and at 6-month intervals over a -year period. Quality assurance was maintained by daily calibration and the use of one
3 Osteoporos Int () 4: phantom. The precision error in BMD was calculated as root mean square (RMS) averages of the standard deviations of repeated measurements. The RMS values of the lumbar spine (L L4) and femoral neck were.7 and. g/cm, respectively. Statistical analysis Results are presented as the mean±sd, unless otherwise indicated. The two groups were compared at baseline to evaluate the success of randomization using unpaired Student s t test. The χ test was used to analyze differences in non-continuous variables between both regimens. Changes in each parameter are represented as percent change from baseline. Repeated measures ANOVA or paired Student s t test was used to compare changes in the variables over time with each treatment. Unpaired Student s t test or Mann Whitney U test was used to analyze changes at each time point between groups. All tests were two-tailed. Statistical significance was assigned at a p<.5 for all analyses. The programs of the SPSS were used for all analyses. Results Baseline characteristics and compliance During the course of the study, there were 5 dropouts in the placebo group and 6 dropouts in the calcium supplementation group. The remaining 4 women (78 in the calcium supplementation group and 65 in the placebo group) completed the -year study. The age of the subjects was 65.8±4.4 years (range, 6 85 years). Dietary calcium intake was 75.6±5.5 mg/day. Serum 5(OH)D was 68.±6. nmol/l. The mean (±SD) compliance of pill taking (by tablet count at each visit) during the -year study period was 89.4±4.8 % in the calcium group and 88.7±7.9 % in the placebo group. At study entry, there were no significant differences between the two groups with regard to clinical characteristics, biochemical parameters, and BMD levels (Table ). The prevalence values of vitamin D insufficiencywerefoundtobe.9and6.%inthecalcium supplementation group and. and 67. % in the placebo group when using a 5(OH)D threshold of 5 Table Baseline clinical and biochemical characteristics and BMD of elderly women in the calcium supplementation and placebo groups Results are the mean±sd or median (range) Characteristics (n=78) (n=65) p value Age (years) 66.± ±4..4 Age at first menstruation (years) 5.±6.6 5.± Age at menopause (years) 49.± ±8..7 BMI (kg/m ) 5.±.5 5.6±.5. No. of Alcohol consumption No. of smokers.48 Sun exposure (h/day), n (%) < > 4 9 Exercise, n (%) Regular 87.6 Sometime No 8 Dietary calcium intake (mg/day) 4. (94.5,4.) 5.6 (5.8,49.).4 Serum calcium (mmol/l).4±..4±..55 Serum inorganic phosphorus (mmol/l).±..±..594 Serum alkaline phosphatase (U/L) 85.± ±.5.55 Serum creatinine (μmol/l) 7.8±7.8 7.±.7. Plasma PTH (pmol/l) 4.7±.9 4.5±.5. Serum 5(OH)D (nmol/l) 69.7±5. 69.±6.5.8 Serum CTx-I (ng/ml).4±..4±.7.95 Serum PINP (ng/ml) 5.±. 5.± Urinary calcium/urinary creatinine.5 (.8.4).46 (.5.99).6 Lumbar spine L L4 BMD (g/cm ).±..±.4.9 Femoral neck BMD (g/cm ).79±..8±..76
4 874 Osteoporos Int () 4: and 75 nmol/l, respectively. Overall,. and 64. % of the subjects had 5(OH)D <5 and 75 nmol/l, respectively. Dietary calcium intake The mean usual calcium intake of the elderly women in the study was 76±8 (SD)mg/day. Almost all subjects (4 in 4 women, 99.4 %) had an average daily calcium intake lower than the current recommendation (, mg/day), and only.8 % (n=) met the recommended dietary reference intake for Thais (8 mg/day). However, the mean daily dietary calcium intake assessed before the beginning of calcium supplementation was similar between groups (Fig. ). According to the treatment assignment, the mean dietary calcium intake in the calcium-treated group was higher than that in the placebo group at subsequent visits up to years. At the end of the study, the mean dietary calcium intakes in the calcium-treated group and the placebo group were 87.± 4.4 and.±47. mg, respectively. homeostasis and biochemical markers of bone turnover At years, serum calcium was increased in both calciumtreated and placebo groups. But the change in serum calcium in the calcium-treated group was significantly higher than in the placebo group (Fig. ). When a comparison was made of the plasma PTH value at years with baseline, there was a non-significant decrease in the plasma PTH of the calcium-treated group, while there was a non-significant increase in the plasma PTH in the placebo group (Fig. ). However, the PTH value of subjects in the calcium-treated group was significantly lower than in the placebo group at the end of the study (p<.). No changes in serum 5(OH)D levels were observed in both calcium group (69.7±5. vs. 68.6±5. nmol/l) and in the placebo group intake (mg/day) Months after enrollment 89 Fig. Total daily calcium intake over years. Values are the mean± SE. Treatment, time, and treatment time interactions were significant (p<.) percent change from baseline at year Serum calcium Plasma PTH calcium placebo Fig. Effect of calcium supplementation on changes in serum calcium and plasma PTH from baseline to years. Values are the mean±se. p<.5 (vs. placebo) (69.±6.5 vs. 68.±4.7 nmol/l). In addition, there was no inverse relationship between change from baseline in serum 5(OH)D and change from baseline in plasma PTH (r=.7, p=.4). Bone turnover markers in the placebo group did not change overtime (Fig. ). On the other hand, both CTx-I and PINP of subjects in the calcium-treated group significantly decreased from baseline (Fig. ). Serum CTx-I % change from baseline Serum PNP % change from baseline Months after enrollment Fig. Percentage change (mean±se) relative to baseline in serum CTx-I and PINP. Treatment, time, and treatment time interactions were significant at each marker (p<.)
5 Osteoporos Int () 4: Bone mineral density There was no significant change in lumbar spine (L L4) BMD in the placebo group, but it increased significantly in the calcium supplementation group (p<.5; Fig. 4). Femoral neck BMD in the calcium-treated group did not change over time, but a significant decline was found in the placebo group (p<.5). Therefore, subjects in the calcium-treated group had higher lumbar spine (L L4) and femoral neck BMDs than subjects in the placebo group (p<.; Fig. 4). To account for the probable interaction between BMD and time since menopause, further analyses were performed every years by the time of menopause ( years, years, and > years). At years of menopause, there was no significant difference between the calcium-treated group and the placebo group in the percent changes from baseline of lumbar spine (L L4; Fig. 5) and femoral neck (Fig. 6)BMD at any time point during the study. However, at more than years of menopause, the calcium-treated group had greater accretion of lumbar spine (L L4) and femoral neck BMD than did the control group (Figs. 5 and 6). Adverse effects The most common adverse effects of calcium are constipation, bloating, cramps, and gas. However, the adverse effects in the calcium supplementation group were not significantly Lumbar spine (L-L4) BMD Percent change from baseline Femoral neck BMD Percent change from baseline months after enrollment Fig. 4 Percentage change (mean±se) relative to baseline in lumbar spine (L L4) and femoral neck BMD. p<. (vs. placebo) Percent change from baseline of lumbar spine (L-L4) BMD Menopause years Menopause - years Menopause > years (n =8) (n = 6) ( n = 8) (n = 9) (n = 4) (n = 7) Fig. 5 Percentage change (mean±se) relative to baseline in lumbar spine (L L4) BMD according to time since menopause. p<. (vs. placebo) Percent change from baseline of femoral neck BMD Menopause years Menopause - years Menopause > years (n =8) (n =6) (n = 8) (n = 9) (n = 4) (n = 7) Fig. 6 Percentage change (mean±se) relative to baseline in femoral neck BMD according to time since menopause. p<. (vs. placebo)
6 876 Osteoporos Int () 4: different from the placebo group (Table ). Elemental calcium supplement for 5 mg/day did not cause hypercalciurea. We found similar levels of 4-h urinary calcium/creatinine ratio in both the calcium supplementation and control groups [.5 ( ) vs..47 (.9 5.4)]. Nonetheless, we also noticed inadequacy of urinary collection in some subjects. Discussion The present study showed the beneficial effects of calcium supplementation on bone. We demonstrated that calcium supplementation of at least 5 mg/day for years in healthy elderly women without osteoporosis or previous osteoporotic fractures modestly increased BMD at lumbar spine, slowed down bone loss at femoral neck, and reduced bone turnover markers. The Institute of Medicine recommends calcium intakes of, mg/day for elderly women []. Even with lower calcium intake than suggested in the recommendation (total calcium intake=87.±4.4 mg in the calcium-treated group), we still noticed the benefit of calcium supplement to bone health. Our findings are consistent with previous reports that calcium supplement might be crucial in people who have low calcium intake at baseline [4, 7]. Our findings are consistent with data from other interventional studies using calcium supplementation as a primary preventive therapy, maintaining bone mineral density, in postmenopausal women. Therefore, calcium supplementation has a protective effect on postmenopausal bone loss; maintaining bone mineral content provides important opportunities for the prevention of osteoporosis and fractures. The effect of calcium supplementation on bone mass in postmenopausal women may be modified by many factors, including the level of dietary of calcium intake, age, genetics, ethnicity, and vitamin D status. supplements have been observed to be most effective in those women in whom the baseline calcium intake was low, the mean age was high, and there was clinical evidence of osteoporosis [4,,, 5]. Our study confirmed the effectiveness of calcium supplement Table Frequency of adverse events between groups (n=78) Constipation Bloating 4 5 Constipation and bloating Bloating and chest tightness Nausea 5 Dizziness Dyspepsia Urticaria Nonspecific 6 Total 7 7 (n=65) in maintaining bone mass in low-calcium-intake subjects. The subjects in our study had daily calcium intakes <4 mg, consistent with previous reports of 4 5 mg of daily calcium intake in Thais [8 ]. The application is the same when we cannot increase the total calcium intake up to,, mg/day according to the standard recommendation []; adding 5 mg of calcium supplement might be of benefit in maintaining bone health in Thai postmenopausal women. Further studies are needed to explore whether increasing the total calcium intake to,, mg/day has additional benefits in maintaining bone health. Studies about the effectiveness of calcium supplement in other groups of Thais, such as in males or younger females, are also warranted. The average calcium intake of elderly Thai women was about a quarter of the current recommended value by the Institute of Medicine of the National Academies []. More than 99 % of the women in the study have less dietary calcium than the recommended level of, mg/day, and only.8 % consumed dietary calcium at the level of 8 mg/day. This is mainly due to the eating habit with limited food source of high calcium, and milk drinking is an uncommon eating habit in the Thai population. The results were consistent with previous studies in other Asian countries where milk is not part of the traditional diet [8 ], confirming that a low dietary calcium intake persists in the Asian population. In addition, we found a lower prevalence of vitamin D deficiency/insufficiency in our subjects when compared with other countries in the same latitude;. and 64. % of subjects had 5(OH)D <5 and 75 nmol/l, respectively. This may imply for the better calcium absorption and maximize the benefit of calcium in maintaining bone health even if the total daily calcium intake is lower than, mg. Studies of direct calcium absorption are needed to confirm this hypothesis. In addition, we found a greater percentage of increased BMD in subjects who were in menopause for more than years in the calcium supplementation group when compared with the control group. On the other hand, such difference was not detected in subjects who were in menopause for < years. Our data correspond to a previous study in which calcium supplementation in the elderly revealed a lesser reduction in BMD and thus a greater reduction in fracture risk when compared with younger age []. In conclusion, supplementation with elemental calcium 5 mg/day alone is able to decrease bone turnover and is effective in retarding bone loss at the lumbar spine and slowing bone loss at the femoral neck in elderly Thai women who had low dietary calcium intake. Dietary calcium augmentation should be recommended as a strategic option in helping to prevent early postmenopausal bone loss. Acknowledgments This study was supported by the Thailand Research Fund and National Health Foundation. Conflicts of interest None.
7 Osteoporos Int () 4: References. Prince RL (994) Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis. Endocr Rev 5: 9. Riggs BL () The mechanisms of estrogen regulation of bone resorption. J Clin Invest 6: 4. Chevalley T, Rizzoli R, Nydegger V, Slosman D, Rapin CH, Michel JP, Vasey H, Bonjour JP (994) Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-d-replete elderly patients. Osteoporos Int 4: Recker RR, Hinders S, Davies KM, Heaney RP, Stegman MR, Lappe JM, Kimmel DB (996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res : Nordin BE (997) and osteoporosis. Nutrition : Prince RL, Devine A, Dhaliwal SS, Dick IM (6) Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 66: Cumming RG, Nevitt MC (997) for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res : 9 8. Chailurkit L, Kruavit A, Rajatanavin R () Vitamin D status and bone health in healthy Thai elderly women. Nutrition 7: Pongchaiyakul C, Nguyen TV, Kosulwat V, Rojroongwasinkul N, Charoenkiatkul S, Eisman JA, Rajatanavin R (4) Effects of physical activity and dietary calcium intake on bone mineral density and osteoporosis risk in a rural Thai population. Osteoporos Int 5:87 8. Piaseu N, Komindr S, Chailurkit L, Ongphiphadhanakul B, Chansirikarn S, Rajatanavin R () Differences in bone mineral density and lifestyle factors of postmenopausal women living in Bangkok and other provinces. J Med Assoc Thai 84: Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium () Dietary reference intakes for calcium and vitamin D (edited by Ross AC, Taylor C, Yaktine AL, Del Valle HB. National Academies Press, Washington, DC. Prentice A (4) Diet, nutrition and the prevention of osteoporosis. Public Health Nutr 7:7 4. Warensjo E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A, Michaelsson K () Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 4:d47 4. Shea B, Wells G, Cranney A et al () Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev : Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (8) The role of calcium and vitamin D in the management of osteoporosis. Bone 4: Wiriyapanich T, Banjong O, Tamachotipong S, Akekantrong P, Wanichakul C, Tanvejasil P () Food composition database for INMUCAL program, nd edn. Institute of Nutrition, Mahidol University, Thailand 7. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S (99) A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med : Kim HS, Kim JS, Kim NS, Kim JH, Lee BK (7) Association of vitamin D receptor polymorphism with calcaneal broadband ultrasound attenuation in Korean postmenopausal women with low calcium intake. Br J Nutr 98: Lau EM, Woo J, Lam V, Hong A () Milk supplementation of the diet of postmenopausal Chinese women on a low calcium intake retards bone loss. J Bone Miner Res 6: Chee WS, Suriah AR, Zaitun Y, Chan SP, Yap SL, Chan YM () Dietary calcium intake in postmenopausal Malaysian women: comparison between the food frequency questionnaire and three-day food records. Asia Pac J Clin Nutr :4 46. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (7) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 5 years and older: a meta-analysis. Lancet 7:
Elecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationPrevalence of Vitamin D insufficiency and low bone mineral density in elderly Thai nursing home residents
Kruavit et al. BMC Geriatrics 2012, 12:49 RESEARCH ARTICLE Open Access Prevalence of Vitamin D insufficiency and low bone mineral density in elderly Thai nursing home residents Anuk Kruavit 1, La-or Chailurkit
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationHigh Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker
J Bone Metab 214;21:189-194 http://dx.doi.org/1.115/jbm.214.21.3.189 pissn 2287-6375 eissn 2287-729 Original Article High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium
More informationAnnie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu
Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation 1 3 Annie WC Kung, Keith DK Luk, LW Chu, and
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationEffect of a Short-Term Treatment with Once-A-Week Medication of Alendronate 70 Mg on Bone Turnover Markers in Postmenopausal Women with Osteoporosis
Effect of a Short-Term Treatment with Once-A-Week Medication of Alendronate 70 Mg on Bone Turnover Markers in Postmenopausal Women with Osteoporosis Likit Rugpolmuang MD*, Saranatra Waikakul MD* * Department
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationV t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s
Vitamin D and Calcium: Role in Prevention and Treatment of Fractures and Falls Osteoporosis 21: New Insights In Research, Diagnosis, and Clinical Care Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationInadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture
J Bone Metab 2016;23:55-61 http://dx.doi.org/10.11005/jbm.2016.23.2.55 pissn 2287-6375 eissn 2287-7029 Original Article Inadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationRobin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson
The skeletal benefits of calcium- and vitamin D 3 fortified milk are sustained in older men after withdrawal of supplementation: an 18-mo follow-up study 1 3 Robin M Daly, Nicole Petrass, Shona Bass, and
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationConcordance of a Self Assessment Tool and Measurement of Bone Mineral Density in Identifying the Risk of Osteoporosis in Elderly Taiwanese Women
TZU CHI MED J September 2008 Vol 20 No 3 available at http://ajws.elsevier.com/tcmj Tzu Chi Medical Journal Original Article Concordance of a Self Assessment Tool and Measurement of Bone Mineral Density
More informationFactors related to bone forming inadequate response to treatment (teriparatide/pth 1-84) in patients with severe osteoporosis. Preliminary results
ORIGINALS / Rev Osteoporos Metab Miner 2015 7;4:85-90 85 Gifre L 1, Monegal A 1, Filella X 2, Muxi A 3, Guañabens N 1, Peris P 1 1 Unidad de Patología Metabólica Ósea - Servicio de Reumatología - Hospital
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationEfficacy, Side Effects, Safety and Effects on Bone Turnover Markers of once a Week Sandoz Alendronate Sodium Trihydrate 70 mg
doi: 10.5704/MOJ.1107.004 Efficacy, Side Effects, Safety and Effects on Bone Turnover Markers of once a Week Sandoz Alendronate Sodium Trihydrate 70 mg Waikakul S, MD, FRCOST, Sintuvanich N, MD, Assanasuwan
More informationChanges in Skeletal Systems over the Lifespan. Connie M. Weaver, Ph.D. Purdue University
Changes in Skeletal Systems over the Lifespan Connie M. Weaver, Ph.D. Purdue University Disclosures Boards/Scientific Advisory Committees ILSI Showalter Pharmavite Grants NIH Dairy Research Institute Nestle
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationNutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives
Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationThe Auckland calcium study: 5-year post-trial follow-up
Osteoporos Int (2014) 25:297 304 DOI 10.1007/s00198-013-2526-z ORIGINAL ARTICLE The Auckland calcium study: 5-year post-trial follow-up L. T. Radford & M. J. Bolland & B. Mason & A. Horne & G. D. Gamble
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationCalcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People
Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,
More informationBone mineral density of patients attending a clinic in Dubai
Bone mineral density of patients attending a clinic in Dubai Freshteh Hosseini Dana 1, Faisal Al-shammari 1, Asma usadiq 1, Maryam Nurudeen Abdurahman 1, Golshid Lotfizadeh 1*, Shatha Al-Sharbatti 2, Rizwana
More informationCALCIUM INTAKE MAY be one of the many factors that
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):707 711 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-1380 Lack of Effect of Calcium Intake
More informationBone mineral density (BMD) and bone-related biochemical markers after short-term supplementation in normal and osteoporotic elders, the pilot study
Journal of Applied Pharmaceutical Science Vol. 8(12), pp 165-169, December, 2018 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2018.81219 ISSN 2231-3354 Bone mineral density (BMD) and
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationBody Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
International Journal of Public Health Science (IJPHS) Vol.3, No.4, December 2014, pp. 276 ~ 280 ISSN: 2252-8806 276 Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationBONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis
BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease
More informationBone Mineral Density in Thai Patients with Chronic Hepatitis C, before and after Treatment with Pegylated Interferon/Ribavirin Combination ABSTRACT
Original Article 73 before and after Treatment with Pegylated Interferon/Ribavirin Combination Bunchorntavakul C 1 Chotiyaputta W 1 Sriussadaporn S 2 Tanwandee T 1 ABSTRACT Background: Loss of bone mineral
More informationWHAT KEEPS OUR BONES STRONG?
WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationThe Better Health News2
October, 2016 Volume11, Issue 10 The Better Health News2 Special Interest Articles: Menopause and Bioflavonoids Osteoporosis and Exercise Bone Health: More than Calcium & Vitamin D Flax Seeds and Menopause
More informationoriginal Se Hwa Kim 1), Tae Ho Kim 1) and Soo-Kyung Kim 2)
Endocrine Journal 2014, 61 (12), 1197-1204 original Effect of high parathyroid hormone level on bone mineral density in a vitamin D-sufficient population: Korea National Health and Nutrition Examination
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationLOVE YOUR BONES Protect your future
www.worldosteoporosisday.org LOVE YOUR BONES Protect your future Know your risk for osteoporosis www.iofbonehealth.org Osteoporosis is a problem worldwide, and in many countries, up to one in three women
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,
More informationHelpful information about bone health & osteoporosis Patient Resource
Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationBONE HEALTH BASICS. Promoting Healthy Bones: Sorting Out the Science. Learning Objectives. Guest Speaker
Copyright 11 by the Preventive Cardiovascular Nurses Association Promoting Healthy Bones: Sorting Out the Science Guest Speaker Robert P. Heaney, MD, FACP, FASN Professor and Professor of Medicine Creighton
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationVitamin D for the Prevention of Osteoporotic Fractures
TITLE: Vitamin D for the Prevention of Osteoporotic Fractures AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department of Medicine University of California
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationSupplemental tables: Abbreviations:
Supplemental tables: Abbreviations: Osteoprotegerin (OPG), Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL), fibroblast growth factor-23 (FGF-23), C-terminal cross-linked telopeptide of type-i
More informationOsteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals. Susan J Whiting University of Saskatchewan
Osteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals Susan J Whiting University of Saskatchewan Learning Objectives Understand the 3 critical nutrients for bone:
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationThe New England Journal of Medicine EFFECT OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER
EFFECT OF CALCIUM AND VITAMIN D SULEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER BESS DAWSON-HUGHES, M.D., SUSAN S. HARRIS, D.SC., ELIZABETH A. KRALL, H.D., AND GERARD E. DALLAL,
More informationAlendronate sodium in the management of osteoporosis
REVIEW Alendronate sodium in the management of osteoporosis P J J Prinsloo 1 D J Hosking 2 1 Dept of Clinical Chemistry, City Hospital, Nottingham, UK; 2 Dept Endocrinology and Diabetes, City Hospital,
More informationThe Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels
CLINICAL RESEARCH STUDY The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels Walid Saliba, MD, MPH, a Ofra Barnett, PhD, a Hedy S. Rennert, MPH, a Idit Lavi, MA, a Gad Rennert, MD, PhD
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism
Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or
More informationComparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women
Original Article Obstet Gynecol Sci 2013;56(3):176-181 http://dx.doi.org/10.5468/ogs.2013.56.3.176 pissn 2287-8572 eissn 2287-8580 Comparison of the efficacy of three once-weekly bisphosphonates on bone
More informationCalcium supplements: benefits and risks
Review Calcium supplements: benefits and risks doi: 10.1111/joim.12394 I. R. Reid 1,2, S. M. Bristow 1 & M. J. Bolland 1 From the 1 Faculty of Medical and Health Sciences, University of Auckland, Auckland;
More informationBiochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake 1 3
Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake 1 3 Patrice Fardellone, Michel Brazier, Saïd Kamel, Jean Guéris, Anne-Marie Graulet, Jacques
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationVitamin D and bone health in a sub-sample of elderly patients from the TUDA 1 Cohort Study.
Vitamin D and bone health in a sub-sample of elderly patients from the TUDA 1 Cohort Study. L Hoey 2, L McAnena 2, JMW Wallace 2, A Molloy 3, C Cunningham 4 and H McNulty 2 1 Trinity, Ulster, Department
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationDietary Protein and Bone Health Emphasis: Animal Protein
USDA-ARS Human Nutrition Research Centers Dietary Protein and Bone Health Emphasis: Animal Protein Z.K. (Fariba) Roughead, PhD, RD Research Nutritionist USDA-ARS Grand Forks Human Nutrition Research Center
More informationA Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More information